Table 2. Centre for Therapeutics Discovery.

Target

Project

Stage of ­development

Collaborator

Undisclosed

Undisclosed

Hit to lead

Undisclosed

Melanocortin 3 receptor (MC3R)

MC3R for inflammatory and mechanical joint disease

Hit to lead

William Harvey Research Institute at Barts and The London School of Medicine and Dentistry

Formyl peptide receptor-like 1 (FPRL1; FPR2)

FPR2 agonists for ischemia/reperfusion injury

Hit to lead

William Harvey Research Institute

Mycobacterium tuberculosis glucanase GlgE (glgE)

Inhibitors of glgE to treat tuberculosis

Hit to lead

John Innes Centre

Melanocortin 2 receptor (MC2R)

MC2R for Cushing's syndrome

Hit to lead

Queen Mary, University of London

MAP/microtubule affinity-regulating kinase (MARK)

Inhibitors of MARK microtubule-associated protein-t (MAPT; TAU; FTDP-17) phosphorylation in Alzheimer's disease (AD)

Hit to lead

MRC Protein Phosphorylation Unit

Neurotrophic tyrosine kinase receptor 1 (NTRK1; TrkA)

TrkA modulators for pain

Hit to lead

University of Bristol

Galanin receptor 1 (GALR1)

New allosteric modulators of the second galanin receptor subtype (GALR2) to treat pain

Screening

University of Bristol

Potassium channel Kir7.1 (KCNJ13)

Inwardly rectifying KCNJ13 to treat postpartum hemorrhage

Screening

The University of Warwick

Plasmodium falciparum exported protein 2 (PKG 123420; EXP2)

Inhibitors of PKG to treat malaria

Hit to lead

London School of Hygiene & Tropical Medicine